Im so pleased we haven’t gone away for the holiday as my son and DIL have decided to come and stay for the weekend.
That really pleases me as its rare to have them stay with us ever since they moved away so I have planned a nice meal on Saturday and then we will go out together Sunday.
They will be trying out and christening our bed settee. I have wanted to do that and never got around to it so now we will see how comfortable it really is.
I will pop out today and buy new pillows and a duvet.
I cant believe I have bought a set of saucepans that are so naff but I have. They have burnt the bottom on making a stew yesterday and the red has gone to orange so I have to buy some more.
I had a very productive day catching up with booking the Hotel for the Mesothelioma UK Patients and Carers Day Oct 4th. Im talking alongside Professor Dean Fennel. Brian Sullivan (Verastem) and Dominic of Saatchi Bill.
The 2014 team of the Saatchi Bill Launch day. Im really looking forward to meeting them again.
I will leave you to read Rays blog on how I lost the remote in bed and we had to search our bedroom out to find it. The crazy things we do amazes me.
We say good night to a lovely Mesowarrior as I have just recieved a message from Ian.
Sandra, who has battled with Meso since diagnosis November 2012 passed away very peacefully at St Wilfrids Hospice on Friday 15th August.
Hugs to you Ian and to your wonderful children Jack and Zoe Naylor at this sad time. Sandra was a brave Mesowarrior xxxx
It makes me so sad to loose another warrior and yet it boosts me on to keep fighting and seeing through this MK3475 Trial as it does seem to be hopeful. I would love to be the one to show the way on something that is going to win our war and I wish we all could have a chance at the drug.
Phase 2 trials might come in next year but what I would like and will fight for is that the drug is Fast Tracked, it does take time and thats what we mesowarriors have not got –TIME is running out and we need to halt the clock.
They can Fast Track if a drug is so good and at the moment MK3475 is giving wonderful results on all trials, not just on Mesothelioma but on all cancers.
Immunotherapy is really looking good and there are no side effects like Chemo which is to our advantage.
A new report I have found———-
BMS and Celgene to research Cancer Immunotherapy Combo
Bristol-Myers Squibb (BMS) is to advance its efforts in cancer immunotherapies via a collaboration with Celgene.
The partnership will see the two companies study a combination of BMS’ anti-PD1 drug Opdivo (nivolumab) and Celenge’s cancer drug Abraxane (paclitaxel).
The combination will be investigated in a phase I study across multiple tumour types, including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer.
“Through this collaboration, Bristol-Myers Squibb and Celgene will work together to advance the science and understanding of how the body’s own immune system and chemotherapy might work together to fight cancer,” said Michael Giordano, senior VP, oncology development, BMS.
Many companies are turning to cancer immunotherapies as the next advance in oncology treatment, with much of the focus on anti-PD1 therapies. Companies that have promising candidates in this class include Merck & Co with the highly promising pembrolizumab, Merck Serono with MSB0010718C and AstraZeneca with MEDI4736.
BMS remains to only company to have an anti-PD1 therapy approved in any country in the world, however, following the decision by regulators in Japan to recommend Opdivo as a treatment for patients with melanoma that is not treatable with surgery.
Opdivo’s rivals are not far behind – Merck & Co’s pembrolizumab is under review in Europe – and the potential for a combination treatment with Abraxane could give BMS a vital edge in the anti-PD1 race.
Positive study results would also benefit Celgene, which currently markets Abraxane as a treatment for pancreatic cancer and metastatic breast cancer.
The phase I trial is expected to begin in the fourth quarter of 2014 and will be conducted by Celgene. Different combinations will be tested in different indications: patients with HER-2 negative breast cancer receive Abraxane and Opdivo; patients with NSCLC will receive Abraxane, carboplatin and Opdivo; and patients with pancreatic adenocarcinoma will be treated with Abraxane, gemcitabine and Opdivo.
Markus Renschler, global head of haematology and oncology medical affairs, Celgene, said: “We believe that Abraxane is appropriate as a combination partner for novel immuno-oncology therapies due to its proven anti-tumour activity and that it can be administered without steroid premedication.”
Additional details of the collaboration were not disclosed.